105 related articles for article (PubMed ID: 8646799)
21. In vitro and in vivo interaction between cisplatin and topotecan in ovarian carcinoma systems.
Romanelli S; Perego P; Pratesi G; Carenini N; Tortoreto M; Zunino F
Cancer Chemother Pharmacol; 1998; 41(5):385-90. PubMed ID: 9523734
[TBL] [Abstract][Full Text] [Related]
22. A truncated human xeroderma pigmentosum complementation group A protein expressed from an adenovirus sensitizes human tumor cells to ultraviolet light and cisplatin.
Rosenberg E; Taher MM; Kuemmerle NB; Farnsworth J; Valerie K
Cancer Res; 2001 Jan; 61(2):764-70. PubMed ID: 11212280
[TBL] [Abstract][Full Text] [Related]
23. Characterization of an ovarian carcinoma cell line resistant to cisplatin and flavopiridol.
Bible KC; Boerner SA; Kirkland K; Anderl KL; Bartelt D; Svingen PA; Kottke TJ; Lee YK; Eckdahl S; Stalboerger PG; Jenkins RB; Kaufmann SH
Clin Cancer Res; 2000 Feb; 6(2):661-70. PubMed ID: 10690552
[TBL] [Abstract][Full Text] [Related]
24. Role of carrier ligand in platinum resistance of human carcinoma cell lines.
Schmidt W; Chaney SG
Cancer Res; 1993 Feb; 53(4):799-805. PubMed ID: 8428361
[TBL] [Abstract][Full Text] [Related]
25. Remission of human breast cancer xenografts on therapy with humanized monoclonal antibody to HER-2 receptor and DNA-reactive drugs.
Pietras RJ; Pegram MD; Finn RS; Maneval DA; Slamon DJ
Oncogene; 1998 Oct; 17(17):2235-49. PubMed ID: 9811454
[TBL] [Abstract][Full Text] [Related]
26. Influence of the proto-oncogene c-fos on cisplatin sensitivity.
Moorehead RA; Singh G
Biochem Pharmacol; 2000 Feb; 59(4):337-45. PubMed ID: 10644041
[TBL] [Abstract][Full Text] [Related]
27. Cisplatin efflux, binding and intracellular pH in the HTB56 human lung adenocarcinoma cell line and the E-8/0.7 cisplatin-resistant variant.
Chau Q; Stewart DJ
Cancer Chemother Pharmacol; 1999; 44(3):193-202. PubMed ID: 10453720
[TBL] [Abstract][Full Text] [Related]
28. Involvement of the mitochondrion respiratory chain in the synergy achieved by treatment of human ovarian carcinoma cell lines with both tumor necrosis factor-alpha and cis-diamminedichloroplatinum.
Uslu R; Bonavida B
Cancer; 1996 Feb; 77(4):725-32. PubMed ID: 8616765
[TBL] [Abstract][Full Text] [Related]
29. Inhibition of DNA repair and sensitization of cisplatin in human ovarian carcinoma cells by interleukin-1 alpha.
Benchekroun MN; Parker R; Reed E; Sinha BK
Biochem Biophys Res Commun; 1993 Aug; 195(1):294-300. PubMed ID: 8363610
[TBL] [Abstract][Full Text] [Related]
30. Gemcitabine potentiates cisplatin cytotoxicity and inhibits repair of cisplatin-DNA damage in ovarian cancer cell lines.
Moufarij MA; Phillips DR; Cullinane C
Mol Pharmacol; 2003 Apr; 63(4):862-9. PubMed ID: 12644587
[TBL] [Abstract][Full Text] [Related]
31. Regulation of cellular response to cisplatin-induced DNA damage and DNA repair in cells overexpressing p185(erbB-2) is dependent on the ras signaling pathway.
Yen L; Nie ZR; You XL; Richard S; Langton-Webster BC; Alaoui-Jamali MA
Oncogene; 1997 Apr; 14(15):1827-35. PubMed ID: 9150389
[TBL] [Abstract][Full Text] [Related]
32. Decreased accumulation as a mechanism of resistance to cis-diamminedichloroplatinum(II) in cervix carcinoma HeLa cells: relation to DNA repair.
Chao CC
Mol Pharmacol; 1994 Jun; 45(6):1137-44. PubMed ID: 8022407
[TBL] [Abstract][Full Text] [Related]
33. Use of host cell reactivation of cisplatin-treated adenovirus 5 in human cell lines to detect repair of drug-treated DNA.
Maynard KR; Hosking LK; Hill BT
Chem Biol Interact; 1989; 71(4):353-65. PubMed ID: 2582540
[TBL] [Abstract][Full Text] [Related]
34. Transport of cisplatin and bis-acetato-ammine-dichlorocyclohexylamine Platinum(IV) (JM216) in human ovarian carcinoma cell lines: identification of a plasma membrane protein associated with cisplatin resistance.
Sharp SY; Rogers PM; Kelland LR
Clin Cancer Res; 1995 Sep; 1(9):981-9. PubMed ID: 9816070
[TBL] [Abstract][Full Text] [Related]
35. Lack of significant modulation of the formation and removal of platinum-DNA adducts by aphidicolin glycinate in two logarithmically-growing ovarian tumour cell lines in vitro.
Dempke WC; Shellard SA; Fichtinger-Schepman AM; Hill BT
Carcinogenesis; 1991 Mar; 12(3):525-8. PubMed ID: 1901253
[TBL] [Abstract][Full Text] [Related]
36. A combination of MSH2 DNA mismatch repair deficiency and expression of the SV40 large T antigen results in cisplatin resistance of mouse embryonic fibroblasts.
Yasin SL; Rainbow AJ
Int J Oncol; 2011 Sep; 39(3):719-26. PubMed ID: 21667017
[TBL] [Abstract][Full Text] [Related]
37. Loss of DNA mismatch repair facilitates reactivation of a reporter plasmid damaged by cisplatin.
Cenni B; Kim HK; Bubley GJ; Aebi S; Fink D; Teicher BA; Howell SB; Christen RD
Br J Cancer; 1999 May; 80(5-6):699-704. PubMed ID: 10360646
[TBL] [Abstract][Full Text] [Related]
38. Decreased cisplatin/DNA adduct formation is associated with cisplatin resistance in human head and neck cancer cell lines.
Yang Z; Faustino PJ; Andrews PA; Monastra R; Rasmussen AA; Ellison CD; Cullen KJ
Cancer Chemother Pharmacol; 2000; 46(4):255-62. PubMed ID: 11052622
[TBL] [Abstract][Full Text] [Related]
39. In vitro studies on the mechanisms of oxaliplatin resistance.
Hector S; Bolanowska-Higdon W; Zdanowicz J; Hitt S; Pendyala L
Cancer Chemother Pharmacol; 2001 Nov; 48(5):398-406. PubMed ID: 11761458
[TBL] [Abstract][Full Text] [Related]
40. Mutant Nbs1 enhances cisplatin-induced DNA damage and cytotoxicity in head and neck cancer.
Tran HM; Shi G; Li G; Carney JP; O'Malley B; Li D
Otolaryngol Head Neck Surg; 2004 Oct; 131(4):477-84. PubMed ID: 15467621
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
